Logo image of ADXN

ADDEX THERAPEUTICS LTD (ADXN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ADXN - US00654J2069 - ADR

7.8 USD
-0.14 (-1.76%)
Last: 1/8/2026, 8:24:32 PM
8 USD
+0.2 (+2.56%)
After Hours: 1/8/2026, 8:24:32 PM
Fundamental Rating

1

Taking everything into account, ADXN scores 1 out of 10 in our fundamental rating. ADXN was compared to 191 industry peers in the Pharmaceuticals industry. ADXN has a bad profitability rating. Also its financial health evaluation is rather negative. ADXN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ADXN has reported negative net income.
In the past year ADXN has reported a negative cash flow from operations.
ADXN had negative earnings in 4 of the past 5 years.
In the past 5 years ADXN always reported negative operating cash flow.
ADXN Yearly Net Income VS EBIT VS OCF VS FCFADXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M -20M

1.2 Ratios

ADXN has a Return On Assets of -77.76%. This is in the lower half of the industry: ADXN underperforms 73.30% of its industry peers.
The Return On Equity of ADXN (-95.67%) is worse than 61.78% of its industry peers.
Industry RankSector Rank
ROA -77.76%
ROE -95.67%
ROIC N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ADXN Yearly ROA, ROE, ROICADXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

ADXN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADXN Yearly Profit, Operating, Gross MarginsADXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

3

2. Health

2.1 Basic Checks

ADXN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADXN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ADXN has more shares outstanding
Compared to 1 year ago, ADXN has an improved debt to assets ratio.
ADXN Yearly Shares OutstandingADXN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K
ADXN Yearly Total Debt VS Total AssetsADXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -60.57, we must say that ADXN is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ADXN (-60.57) is worse than 93.19% of its industry peers.
ADXN has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ADXN has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: ADXN outperforms 59.69% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -60.57
ROIC/WACCN/A
WACC4.93%
ADXN Yearly LT Debt VS Equity VS FCFADXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

ADXN has a Current Ratio of 2.01. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
ADXN has a Current ratio of 2.01. This is in the lower half of the industry: ADXN underperforms 61.26% of its industry peers.
ADXN has a Quick Ratio of 2.01. This indicates that ADXN is financially healthy and has no problem in meeting its short term obligations.
ADXN has a Quick ratio (2.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 2.01
ADXN Yearly Current Assets VS Current LiabilitesADXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

ADXN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -210.12%.
The Revenue has decreased by -6.26% in the past year.
ADXN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -32.07% yearly.
EPS 1Y (TTM)-210.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
Revenue 1Y (TTM)-6.26%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-15.07%

3.2 Future

ADXN is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -16.49% yearly.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.49%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ADXN Yearly Revenue VS EstimatesADXN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
ADXN Yearly EPS VS EstimatesADXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 0 -20 -40 -60

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADXN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADXN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADXN Price Earnings VS Forward Price EarningsADXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADXN Per share dataADXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

ADXN's earnings are expected to decrease with -25.99% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADXN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ADDEX THERAPEUTICS LTD

NASDAQ:ADXN (1/8/2026, 8:24:32 PM)

After market: 8 +0.2 (+2.56%)

7.8

-0.14 (-1.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-04 2025-12-04/bmo
Earnings (Next)04-06 2026-04-06/amc
Inst Owners1.13%
Inst Owner Change0%
Ins Owners5.96%
Ins Owner ChangeN/A
Market Cap7.23M
Revenue(TTM)555.30K
Net Income(TTM)-5.70M
Analysts40
Price TargetN/A
Short Float %1.71%
Short Ratio0.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-12.09%
EPS NY rev (3m)-32.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.37
P/FCF N/A
P/OCF N/A
P/B 0.97
P/tB 0.97
EV/EBITDA N/A
EPS(TTM)-8.64
EYN/A
EPS(NY)-6.23
Fwd EYN/A
FCF(TTM)-2.13
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS0.75
BVpS8.07
TBVpS8.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -77.76%
ROE -95.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.51%
ROA(5y)-108.73%
ROE(3y)-424.03%
ROE(5y)-289.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 2.01
Altman-Z -60.57
F-Score2
WACC4.93%
ROIC/WACCN/A
Cap/Depr(3y)0.97%
Cap/Depr(5y)5.54%
Cap/Sales(3y)0.26%
Cap/Sales(5y)0.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-210.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.68%
EPS Next Y-1500%
EPS Next 2Y-216.23%
EPS Next 3Y-25.99%
EPS Next 5Y-16.49%
Revenue 1Y (TTM)-6.26%
Revenue growth 3Y-49.34%
Revenue growth 5Y-32.07%
Sales Q2Q%-15.07%
Revenue Next Year-21.42%
Revenue Next 2Y-11.36%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y58.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.67%
EBIT Next 3Y5.45%
EBIT Next 5Y5.93%
FCF growth 1Y84.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y84.91%
OCF growth 3YN/A
OCF growth 5YN/A

ADDEX THERAPEUTICS LTD / ADXN FAQ

What is the fundamental rating for ADXN stock?

ChartMill assigns a fundamental rating of 1 / 10 to ADXN.


What is the valuation status for ADXN stock?

ChartMill assigns a valuation rating of 0 / 10 to ADDEX THERAPEUTICS LTD (ADXN). This can be considered as Overvalued.


Can you provide the profitability details for ADDEX THERAPEUTICS LTD?

ADDEX THERAPEUTICS LTD (ADXN) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ADDEX THERAPEUTICS LTD?

The Earnings per Share (EPS) of ADDEX THERAPEUTICS LTD (ADXN) is expected to decline by -1500% in the next year.